Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy and a
leading case of childhood cancer death. The last decade has witnessed a transformation in …

Acute lymphoblastic leukemia (ALL), the most common malignancy of childhood, is a
genetically complex entity that remains a major cause of childhood cancer‐related mortality …

Advances in genomic research and risk-directed therapy have led to improvements in the
long-term survival and quality of life outcomes of patients with childhood acute lymphoblastic …

Acute lymphoblastic leukemia (ALL) is the most common malignancy in childhood,
accounting for almost 30% of pediatric cancers. Despite the high rate of cure, ALL is one of …

A key goal in cancer research is to identify the total complement of genetic and epigenetic
alterations that contribute to tumorogenesis. We are currently witnessing the rapid evolution …

Major advances in genetic and epigenetic profiling of acute lymphoblastic leukaemia (ALL)
have enhanced the understanding of key biological subsets of de novo and relapsed ALL …

Genomic profiling has transformed our understanding of the genetic basis of acute
lymphoblastic leukemia (ALL). Recent years have seen a shift from microarray analysis and …

Acute lymphoblastic leukemia (ALL) is characterized by genetic alterations that block
differentiation, promote proliferation of lymphoid precursor cells, and are important for risk …

Acute lymphoblastic leukaemia (ALL) is the commonest childhood cancer and an important
cause of morbidity from haematological malignancies in adults. In the past several years, we …

Despite impressive advances in cure rates for childhood acute lymphoblastic leukemia
(ALL), ALL remains the leading cause of disease-related death in young people and new …